Do perinatal CBT-I studies follow participants long enough to support claims about lasting depression prevention?

What would count as long enough to claim lasting prevention?

Perinatal depression risk does not stop at delivery. It can emerge during pregnancy or in the months after birth, which is why a prevention claim needs to cover the postpartum period, not just the weeks right after treatment ends. A trial that stops measuring at, say, ten weeks after randomization could miss depression that appears later in the first postpartum year.

The PRISM trial sets the bar explicitly: it aims to follow pregnant participants with insomnia through 12 months postpartum, with assessments at 3, 6, 9, and 12 months after birth, and it names depression incidence measured by a structured diagnostic interview as the primary outcome [1]. That design, if completed, would directly test whether digital CBT-I prevents depression across the whole window when perinatal risk is elevated. The key word is "if" — the protocol reports that data collection began in November 2022 and is projected to end in December 2026, so the follow-up exists as a plan, not as evidence [1].

Why treat sleep to prevent depression at all?

The rationale is that insomnia is a modifiable risk factor for depression, and the protocol notes that research in non-pregnant populations, plus preliminary findings in pregnant people, suggests that targeting insomnia with digital CBT-I may prevent depression [1]. The intervention itself is a structured digital program using sleep consolidation, stimulus control, cognitive therapy, relaxation, and sleep hygiene education across six short modules, compared against sleep hygiene handouts alone [1].

That comparison matters for interpreting any future result. Sleep hygiene education is described as a credible, clinically relevant comparator rather than a do-nothing control, so a benefit of digital CBT-I would mean something beyond generic sleep advice [1]. The trial also plans to measure mediators such as insomnia severity, sleep diary data, and repetitive negative thinking, which could help explain how and for whom prevention works — but those are proposed mechanisms to be tested, not established ones [1].

Other long follow-ups exist, but not in this population

Several studies in this area do track people for a year, which can create a misleading impression that the perinatal question is settled. A stepped-care trial of digital and face-to-face CBT-I followed 1,018 adults with insomnia and no depression and found that at one year, clinically significant depression was 2.4 times more common in those who received the control at the second step (13.2%) than in those who received face-to-face CBT-I (5.5%) [3]. That is a meaningful signal about depression prevention one year out, but the participants were general adults with insomnia, not pregnant or postpartum people, so it cannot be transferred directly to perinatal care [3].

Two other long-follow-up studies are even further from the question. A 12-month follow-up of CBT and Ericksonian hypnotherapy for subclinical depression and anxiety found improvements largely maintained, with only minor attenuation, but it studied neither CBT-I nor a perinatal group [2]. A trial combining CBT with amygdala neurofeedback in adults with major depression reported higher remission at 6 months and 1 year, again in a general adult sample with no perinatal focus [5]. Both suggest that psychological depression interventions can have durable effects, yet neither speaks to whether CBT-I given around pregnancy prevents depression later.

So what can be said today?

The honest summary is that the perinatal evidence base is still being built. One study in this set designed a social media group CBT intervention for perinatal youth and documented stakeholder input on stigma, isolation, and access to care, but it reports no follow-up outcome data, so it says nothing about lasting prevention [4]. The PRISM protocol is the only perinatal CBT-I trial here with a long-horizon depression outcome, and its results are not yet available [1].

That leaves a clear distinction between plausibility and proof. It is plausible, based on non-pregnant samples and preliminary perinatal findings, that digital CBT-I could reduce later depression [1], and one-year prevention signals in general adult insomnia samples are encouraging [3]. But a claim that perinatal CBT-I durably prevents depression should wait for the 12-month postpartum data to be reported, because until then the follow-up is a commitment in a protocol rather than a finding [1].

Sources used in this answer

Related research questions